Titan Cement International SA (TITC)
Euronext Brussels · Belgium · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 46.80 |
|---|---|
| 52-week range | 38.10 – 58.90 |
| Return, 1 month / 3 months | −5.6% / −7.7% |
| Return, 1 year / 3 years | +23.2% / +221.4% |
| Trend | Below its 200-day average |
| RSI (14) | 40 |
| Volatility (1 year) | 31.0% |
| Worst drawdown (1 year) | -25.9% |
| Average daily value traded | 0.38M EUR |
| Dividend yield | 2.4% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Titan Cement International is a building materials group based in Greece that makes cement and clinker, and also supplies aggregates, ready-mix concrete and related products. Its customers are construction firms, concrete producers, contractors and infrastructure projects, served through plants and terminals in Greece, the wider eastern Mediterranean region, the Balkans, Egypt and the United States, where its Titan America business operates cement and concrete facilities.
On this site Titan Cement International SA appears as a stock on the Euronext Brussels (Belgium), code TITC, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Titan Cement International SA (TITC) trades on the Euronext Brussels in Belgium. It last closed at EUR 46.80 on 22 October 2026.
Its price-based Market X-Ray is 54 out of 100 (a fair price profile), ranking 55 of 111 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 23.2% and over the last three months it fell 7.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Brussels
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 51 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -5.6% | ||
| From 52-week high | -20.0% | ||
| Momentum | 65 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -7.7% | ||
| 6-month return | 3.0% | ||
| 12-month return, skipping the last month | 30.5% | ||
| Stability (higher is calmer) | 46 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 31.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -25.9% | ||
| Liquidity | 62 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.38M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 46 · Weak | Dividend is small or irregular. | |
| Dividend yield | 2.4% | ||
| Years with dividends | 5 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | −1.3% |
|---|---|
| 1 month | −5.6% |
| 3 months | −7.7% |
| 6 months | +3.0% |
| 1 year | +23.2% |
| 3 years | +221.4% |
| 5 years | +278.0% |
Signals
| 50-day / 200-day average | 49.74 / 49.59 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.01 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 1 Jul 2026 | EUR 1.1000 |
| 30 Jun 2025 | EUR 3.0000 |
| 25 Jun 2024 | EUR 0.8500 |
| 28 Jun 2023 | EUR 0.6000 |
| 27 Apr 2022 | EUR 0.5000 |
| 12 May 2021 | EUR 0.4000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Brussels; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.